ATC Group: A10BX03 Nateglinide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BX03 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BX Other blood glucose lowering drugs, excl. insulins
5 A10BX03 Nateglinide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.36 g

Active ingredients in A10BX03

Active Ingredient Description
Nateglinide

Nateglinide is an amino acid (phenylalanine) derivative, which is chemically and pharmacologically distinct from other antidiabetic agents. Nateglinide is a rapid, short-acting oral insulin secretagogue. Its effect is dependent on functioning beta cells in the pancreas islets.

Related product monographs

Title Information Source Document Type  
STARLIX Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Cyprus (CY)

Estonia (EE)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.